Research Roundup

Debbie Rigby takes a look at the latest in research news

Medication-related osteonecrosis of the jaw

Analysis of the Australian database of adverse event notifications identified medications reported to cause osteonecrosis of the jaw, including adalimumab, etanercept, methotrexate and rituximab. The majority of reported cases occurred with bisphosphonates and denosumab. The most common trigger for medication-related ONJ is an invasive dental procedure, with extractions being the most frequently implicated.

British Journal of Clinical Pharmacology 2021;87(7):2767-76.


Improving Adherence to Topical Medication in Patients with Glaucoma

This review article summarises the available evidence regarding potential methods for the improvement of adherence to topical anti-glaucoma medication. Interventions to improve adherence include automated reminders, use instillation aids, improving communication with patient education and improving tolerability of eye drop formulations. Key strategies include schedule simplicity, ease of administration, minimisation of side effects and promotion of self-efficacy.

Patient Preference and Adherence 2021;15:1477–1489.


Efficacy and Safety of As-Needed Budesonide-Formoterol in Adolescents with Mild Asthma

This post hoc pooled analysis of Symbicort Given as-needed in Mild Asthma (SYGMA) 1 and 2 assessed the efficacy and safety of as-needed budesonide/formoterol in adolescents. Severe exacerbation rate was similar with as-needed budesonide/formoterol and budesonide maintenance; and was significantly lower with as-needed budesonide/formoterol versus as-needed terbutaline. The authors concluded as-needed budesonide/formoterol provides an alternative treatment option for adolescents with mild asthma, without needing daily treatment.

Journal of Allergy and Clinical Immunology In Practice, 2021.


Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes

The results of this cohort study provide real-world data on the risk of all-cause mortality associated with sodium-glucose cotransporter 2 inhibitors vs sulfonylureas. Use of SGLT2 inhibitors with metformin therapy was associated with a 19% reduced risk of all-cause mortality compared with sulfonylureas, regardless of cardiovascular disease status, estimated glomerular filtration rate category, and albuminuria status. There was also a 30% reduced risk of death with the combination of SGLT2 inhibitor and metformin compared with SGLT2 inhibitor use alone.

JAMA Internal Medicine, Published online June 28, 2021.



Previous AJP chats with… Verity Boustead
Next $12 billion saving if all qualified pharmacists can COVID vaccinate

NOTICE: It can sometimes take awhile for comment submissions to go through, please be patient.

No Comment

Leave a reply